Europe's Big Pharma Could Win Investors' Favor With Busy End of Year -- Market Talk

Dow Jones06-10

1434 GMT - Big European pharmaceutical companies have a busy second half of the year, with several key events that could help them build positive outlooks and win investors' favor, Bank of America analysts say in a note. Novartis and AstraZeneca have the busiest schedules in terms of results of clinical studies, the analysts say. At GSK and Sanofi, recently appointed CEOs are expected to provide updates on their plans alongside second-quarter earnings, they add. For Novo Nordisk, the main focus remains on prescription trends for its obesity and diabetes products, BofA says. Roche faces a quieter second half, but the launch of its new breast-cancer drug giredestrant will be key, the analysts write. The Stoxx Europe 600 Health Care index is up 0.5%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 10, 2026 10:34 ET (14:34 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642424085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642424085","market":"us","top_or_hot":-1,"title":"Europe's Big Pharma Could Win Investors' Favor With Busy End of Year -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1434 GMT - Big European pharmaceutical companies have a busy second half of the year, with several key events that could help them build positive outlooks and win investors' favor, Bank of America analysts say in a note. Novartis and AstraZeneca have the busiest schedules in terms of results of clinical studies, the analysts say. At GSK and <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, recently appointed CEOs are expected to provide updates on their plans alongside second-quarter earnings, they add. For <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the main focus remains on prescription trends for its obesity and diabetes products, BofA says. Roche faces a quieter second half, but the launch of its new breast-cancer drug giredestrant will be key, the analysts write. The Stoxx Europe 600 Health Care index is up 0.5%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 10, 2026 10:34 ET (14:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Europe's Big Pharma Could Win Investors' Favor With Busy End of Year -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEurope's Big Pharma Could Win Investors' Favor With Busy End of Year -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-10 22:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1434 GMT - Big European pharmaceutical companies have a busy second half of the year, with several key events that could help them build positive outlooks and win investors' favor, Bank of America analysts say in a note. Novartis and AstraZeneca have the busiest schedules in terms of results of clinical studies, the analysts say. At GSK and <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, recently appointed CEOs are expected to provide updates on their plans alongside second-quarter earnings, they add. For <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>, the main focus remains on prescription trends for its obesity and diabetes products, BofA says. Roche faces a quieter second half, but the launch of its new breast-cancer drug giredestrant will be key, the analysts write. The Stoxx Europe 600 Health Care index is up 0.5%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 10, 2026 10:34 ET (14:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2642424085","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642424085","pubTimestamp":1781102040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1434 GMT - Big European pharmaceutical companies have a busy second half of the year, with several key events that could help them build positive outlooks and win investors' favor, Bank of America analysts say in a note. Novartis and AstraZeneca have the busiest schedules in terms of results of clinical studies, the analysts say. At GSK and Sanofi, recently appointed CEOs are expected to provide updates on their plans alongside second-quarter earnings, they add. For Novo Nordisk, the main focus remains on prescription trends for its obesity and diabetes products, BofA says. Roche faces a quieter second half, but the launch of its new breast-cancer drug giredestrant will be key, the analysts write. The Stoxx Europe 600 Health Care index is up 0.5%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","03165":"华夏欧优股对冲","NVOH":"Novo Nordisk A/S B Shares ADRhedged","AZN":"阿斯利康","LU0058720904.USD":"联博国际健康护理基金A","BK4532":"文艺复兴科技持仓","NVOX":"2倍做多NVO ETF-Defiance","GSK":"葛兰素史克","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4599":"减肥药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","RHHBY":"罗氏控股","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","NVO":"诺和诺德","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4578":"CAR-T","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","NVS":"诺华","GSK.UK":"葛兰素史克","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","GSKH":"GSK plc ADRhedged","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","BK4568":"美国抗疫概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4588":"碎股","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4007":"制药"},"translate_title":"欧洲大型制药公司可能会在繁忙的年底赢得投资者的青睐——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1.89,"NVS":1.89,"AZNH":0.6,"RHHBY":1.87,"GSKH":0.6,"NVOX":0.6,"GSK":1.87,"NVOH":0.6,"GSK.UK":0.6,"NVO":1.87,"03165":0.6},"content_text":"1434 GMT - Big European pharmaceutical companies have a busy second half of the year, with several key events that could help them build positive outlooks and win investors' favor, Bank of America analysts say in a note. Novartis and AstraZeneca have the busiest schedules in terms of results of clinical studies, the analysts say. At GSK and Sanofi, recently appointed CEOs are expected to provide updates on their plans alongside second-quarter earnings, they add. For Novo Nordisk, the main focus remains on prescription trends for its obesity and diabetes products, BofA says. Roche faces a quieter second half, but the launch of its new breast-cancer drug giredestrant will be key, the analysts write. The Stoxx Europe 600 Health Care index is up 0.5%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2026 10:34 ET (14:34 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642424085","isCrawlerRequest":true}